Futura Medical PLC

Receive alerts
Market Cap:
£28.25 m
11.50 GBX
52 weeks high
52 weeks low

In brief

Futura Medical is an innovative R&D company with a pipeline of products in late stage development. We are experts in transdermal delivery and have developed an advanced proprietary transdermal technology, DermaSys®. Our lead product MED2005, is a breakthrough topical treatment for erectile dysfunction currently in Phase 3 clinical trial with potential peak sales of $1bn1. Our strategy is to develop our innovative product portfolio to late stage and then to partner with major pharmaceutical partners. We are based in Guildford, UK and are listed on the AIM market of the London Stock Exchange.

Deep dive We explore the investor case for growth companies


  • Developing fast-acting gels for erectile dysfunction and pain relief
  • Phase III trial of MED2005 for ED delivered a surprise result that hit the shares
  • Yet the outcome could make it cheaper and simpler to gain regulatory approval

Caption: Many men aren't able to use the current crop of blue pills because of their side effects